ATE381624T1 - Retrovirale vektoren mit verminderter rekombinationsrate - Google Patents

Retrovirale vektoren mit verminderter rekombinationsrate

Info

Publication number
ATE381624T1
ATE381624T1 AT95920386T AT95920386T ATE381624T1 AT E381624 T1 ATE381624 T1 AT E381624T1 AT 95920386 T AT95920386 T AT 95920386T AT 95920386 T AT95920386 T AT 95920386T AT E381624 T1 ATE381624 T1 AT E381624T1
Authority
AT
Austria
Prior art keywords
pol
gag
expression cassettes
env
ltr
Prior art date
Application number
AT95920386T
Other languages
English (en)
Inventor
James G Respess
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE381624T1 publication Critical patent/ATE381624T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Ceramic Products (AREA)
  • Optical Radar Systems And Details Thereof (AREA)
AT95920386T 1994-05-09 1995-05-09 Retrovirale vektoren mit verminderter rekombinationsrate ATE381624T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24003094A 1994-05-09 1994-05-09

Publications (1)

Publication Number Publication Date
ATE381624T1 true ATE381624T1 (de) 2008-01-15

Family

ID=22904813

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95920386T ATE381624T1 (de) 1994-05-09 1995-05-09 Retrovirale vektoren mit verminderter rekombinationsrate

Country Status (8)

Country Link
EP (2) EP0772689B1 (de)
JP (1) JP4303315B2 (de)
AT (1) ATE381624T1 (de)
AU (1) AU2585395A (de)
CA (1) CA2158977A1 (de)
DE (1) DE69535669T2 (de)
ES (1) ES2297831T3 (de)
WO (1) WO1995030763A2 (de)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US5698446A (en) * 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
EP0852626B1 (de) * 1996-01-29 2002-04-03 Virologic, Inc. Verfahren und zusammensetzungen zur bestimmung der empfindlichkeit und resistenz gegen antivirale wirkstoffe und screening für antivirale wirkstoffe
WO1997035995A1 (fr) * 1996-03-25 1997-10-02 Transgene S.A. Compositions cellulaires antitumorales exprimant au moins trois transgenes
WO1997035996A1 (en) * 1996-03-25 1997-10-02 Transgene S.A. Packaging cell line based on human 293 cells
WO1997042338A1 (en) * 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
GB2322131B (en) * 1996-09-21 2000-12-20 Viromedica Pacific Ltd Improved retroviral vectors for gene therapy
WO1999020311A1 (en) * 1997-10-21 1999-04-29 Chiron Corporation METHODS FOR CANCER IMMUNOTHERAPY USING RETROVIRAL VECTORS EXPRESSING η INTERFERON
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
WO1999025862A2 (en) * 1997-11-19 1999-05-27 Nature Technology, Inc. Chimeric viral packaging signal without gag gene sequences
ES2373406T3 (es) * 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
GB2356200B (en) * 1997-12-22 2002-05-01 Oxford Biomedica Ltd Retroviral vectors
EP1047784B2 (de) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Antigene aus neisseria meningitidis
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6451304B1 (en) 1998-03-09 2002-09-17 The Regents Of The University Of California Method for retrovirus vector production by separated gag and pol expression
EP2261338A3 (de) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
JP2004508801A (ja) 1999-10-29 2004-03-25 カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ ナイセリア抗原性ペプチド
EP2163626A1 (de) 1999-11-18 2010-03-17 Novartis Vaccines and Diagnostics, Inc. Menschliches FGF-21 Gen und Genexpressionsprodukte
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
EP1854476A3 (de) 2000-02-09 2008-05-07 Bas Medical, Inc. Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten
NZ521531A (en) 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
WO2001066595A2 (en) 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
WO2003057926A1 (en) 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
ES2305087T3 (es) 2000-06-15 2008-11-01 Novartis Vaccines And Diagnostics, Inc. Polinucleotidos relacionados con el cancer de colon.
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
JP2004535765A (ja) 2000-12-07 2004-12-02 カイロン コーポレイション 前立腺癌においてアップレギュレートされた内因性レトロウイルス
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
KR100440852B1 (ko) * 2001-05-10 2004-07-19 주식회사 바이로메드 레트로바이러스에 특이적인 올리고뉴클레오티드 프라이머및 이를 이용한 레트로바이러스 농도 측정방법
WO2003039491A2 (en) 2001-11-09 2003-05-15 Georgetown University Novel isoforms of vascular endothelial cell growth inhibitor
RU2331435C2 (ru) 2001-12-12 2008-08-20 Чирон Срл. Иммунизация против chlamydia trachomatis
EP2093233A1 (de) 2002-03-21 2009-08-26 Sagres Discovery, Inc. Neue Zusammensetzungen und Verfahren bei Krebs
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EP1562982B1 (de) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unerwartete oberflächenproteine in neisseria meningitidis
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
JP2007524362A (ja) 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
BRPI0407375A (pt) 2003-02-19 2006-02-07 Rinat Neuroscience Corp Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
AP2006003670A0 (en) 2003-12-23 2006-06-30 Rinat Neuroscience Corp Agonist anti-TRKC antibodies and methods using same
EP1723247A4 (de) * 2004-03-01 2007-10-03 Peter Maccallum Cancer Inst Rekombinantes perforin, dessen expression und verwendungen
EP3372614B1 (de) 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Verfahren zur schmerzbehandlung in knochenkrebs durch verabreichung eines ngf-antagonististen
AU2005327194B2 (en) 2004-07-09 2010-09-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus G glycoprotein
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
EP1865981A2 (de) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e in der diagnose und nachweis von sowie als therapeutisches mittel gegen krebs
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
EP1907425B1 (de) 2005-07-22 2014-01-08 Y's Therapeutics Co., Ltd. Anti-cd26-antikörper und verfahren zu ihrer verwendung
EP3069731A1 (de) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonistische antikörper gegen calcitoningen-assoziiertes peptid und verfahren damit
CA2652703C (en) 2006-06-07 2018-08-28 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli
US20100261640A1 (en) 2007-04-10 2010-10-14 Branco Luis M Soluble and membrane anchored forms of lassa virus subunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
BRPI0822049B1 (pt) 2007-12-17 2021-11-16 Pfizer Limited Composiqao farmaceutica compreendendo anticorpo antagonista anti-ngf, kit e uso de um anticorpo antingf
HUE026846T2 (en) 2007-12-18 2016-08-29 Bioalliance Cv Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use
EP3023502A1 (de) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
EP3263128A3 (de) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Zusammensetzungen zur immunisierung gegen staphylococcus aureus
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012075243A2 (en) 2010-12-01 2012-06-07 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
TWI495644B (zh) 2011-11-11 2015-08-11 Rinat Neuroscience Corp 營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途
US9249224B2 (en) 2011-12-22 2016-02-02 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
CA2877948C (en) 2012-07-02 2019-07-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Paramyxovirus and methods of use
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
CA2890483A1 (en) 2012-11-09 2014-05-15 Robert ARCH Platelet-derived growth factor b specific antibodies and compositions and uses thereof
AU2014240045A1 (en) 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
WO2014181229A2 (en) 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CA2919790C (en) 2013-08-02 2018-06-19 Pfizer Inc. Anti-cxcr4 antibodies and antibody-drug conjugates
US9683998B2 (en) 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6894236B2 (ja) 2014-03-26 2021-06-30 デノボ バイオファーマ エルエルシー 免疫刺激活性を有するレトロウイルスベクター
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN107405399B (zh) 2015-01-02 2022-02-08 武田药品工业株式会社 针对血浆激肽释放酶和因子xii的双特异性抗体
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
AU2016297018B9 (en) 2015-07-21 2022-12-01 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor XIIa
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
KR102438650B1 (ko) 2015-08-19 2022-08-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN109219618B (zh) 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
AU2017290805B2 (en) 2016-07-01 2023-11-16 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
CA3054885A1 (en) 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof
WO2018167621A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
EP3615570A4 (de) 2017-04-25 2021-02-24 LBL Biotechnology Inc. Verwendung von il-20-antagonisten zur behandlung von augenerkrankungen
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
GB202209539D0 (en) 2017-06-13 2022-08-10 Bostongene Corp Systems and methods for identifying cancer treatments from normalized biomarker scores
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
EP3692370A2 (de) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Artikel und verfahren zur personalisierten krebstherapie
CA3080120C (en) 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
PE20210708A1 (es) 2018-02-01 2021-04-16 Pfizer Anticuerpos especificos para cd70 y sus usos
CN112020518A (zh) 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
AU2019228381B2 (en) 2018-02-28 2021-12-16 Pfizer Inc. IL-15 variants and uses thereof
EP3758737A4 (de) 2018-03-02 2022-10-12 Kodiak Sciences Inc. Il-6-antikörper und fusionskonstrukte und konjugate davon
KR102602329B1 (ko) 2018-05-23 2023-11-16 화이자 인코포레이티드 Cd3에 특이적인 항체 및 이의 용도
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
JP7603580B2 (ja) 2018-10-15 2024-12-20 エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド 顆粒球マクロファージコロニー刺激因子に対する抗体及びそれらの使用
EP3897706A4 (de) 2018-12-21 2022-11-23 Griffith University Zusammensetzungen, verfahren und verwendungen zur auslösung einer immunreaktion
WO2020132190A1 (en) 2018-12-21 2020-06-25 Multitude Inc. Antibodies specific to muc18
US12084500B2 (en) 2019-01-23 2024-09-10 New York University Antibodies specific to delta 1 chain of T cell receptor
US12205675B2 (en) 2019-07-03 2025-01-21 Bostongene Corporation Techniques for bias correction in sequence data
WO2021071830A1 (en) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072244A1 (en) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
US20230235007A1 (en) 2020-06-15 2023-07-27 Ming-Che Shih Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
MX2023000662A (es) 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
CA3190227A1 (en) 2020-07-30 2022-02-03 Pfizer Inc. Cells having gene duplications and uses thereof
US12254961B2 (en) 2020-12-04 2025-03-18 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
JP2024517745A (ja) 2021-04-29 2024-04-23 ボストンジーン コーポレイション 複合腫瘍組織における腫瘍細胞発現を推定するための機械学習技法
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
CA3249858A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation MACHINE LEARNING TECHNIQUES FOR CYTOMETRY
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
US20260120879A1 (en) 2023-10-31 2026-04-30 Bostongene Corporation Machine learning technique for identifying ici responders and non-responders
US20250253011A1 (en) 2024-02-02 2025-08-07 Seven Bridges Genomics Inc. Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0133123A1 (de) 1983-07-25 1985-02-13 Mgi Pharma, Inc. Papillomavirus-Immunogene
EP0173254B1 (de) 1984-08-23 1991-07-24 Hans Joachim Wolf DNA-Sequenzen des EBV-Genoms, rekombinante DNA-Moleküle, Verfahren zur Herstellung von EBV-verwandten Antigenen sowie diagnostische Zusammensetzungen und pharmazeutische Zusammensetzungen, die die genannten Antigene enthalten
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
US4939088A (en) 1987-02-18 1990-07-03 Meloy Laboratories Inc. Sustained production of recombinant gamma interferon using an Epstein-Barr virus replicon
CA1341439C (en) 1987-08-26 2003-09-23 Niels C. Pedersen Feline t-lymphotropic lentivirus
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
JP2694228B2 (ja) 1987-11-12 1997-12-24 壹夫 柳 抗ｅｂｎａ抗体の測定法
CA1315719C (en) * 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
WO1990002806A1 (en) * 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
ATE140483T1 (de) 1988-11-10 1996-08-15 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
ES2179854T3 (es) 1988-12-13 2003-02-01 Harvard College Materiales aislados de felv prototipos para uso en modelos de enfermedades y vacunas.
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
JP3058685B2 (ja) 1989-05-08 2000-07-04 アイデックス ラボラトリーズ インコーポレーテッド ネコｔ細胞リンパトロピック レンチウィルスのポリペプチド
DE69034249T2 (de) 1989-12-22 2008-05-29 F. Hoffmann-La Roche Ag Monoklonale Antikörper spezifisch für den zytotoxischen Lymphozyten-Reifefaktor
EP0854193A1 (de) 1990-09-21 1998-07-22 Chiron Corporation Humanische Retroviren- Packaging Zellinie
CN1067382A (zh) 1990-09-26 1992-12-30 布里斯托尔-迈尔斯斯奎尔公司 人类乳头状瘤病毒肽的表达以及在致免疫组合物中的应用
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ES2096750T3 (es) * 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
US6228608B1 (en) 1991-02-28 2001-05-08 Aquila Biopharmaceuticals, Inc. Recombinant FIV glycoprotein 160 and P24 gag protein
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5226600A (en) 1991-08-02 1993-07-13 Wagner Spray Tech Corporation Check valve
FR2683226B1 (fr) 1991-10-30 1995-06-09 Univ Paris Curie Cellules piegees a l'egard d'antigenes provoquant le dysfonctionnement du systeme immunitaire, medicaments pour la prevention ou le traitement de maladies induites par ces dysfonctionnements.
EP0564645B1 (de) 1991-10-30 1999-12-29 Universite Pierre Et Marie Curie Paris Vi Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren
GB9123377D0 (en) 1991-11-02 1991-12-18 Epro Uk Ltd Coating of surface with bitumen membrane
AU672372B2 (en) 1991-11-08 1996-10-03 Pharmacia & Upjohn Company Feline leukemia virus vaccines
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
JPH07501942A (ja) 1991-11-29 1995-03-02 カイロン　コーポレイション 抗ガン免疫療法用ベクター構成体
DK0625204T3 (da) 1992-02-04 2002-07-15 Chiron Corp Terapeutiske midler mod hepatitis
WO1994004680A1 (en) 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
US5306800A (en) 1992-11-09 1994-04-26 Hoechst Celanese Corp. Pseudo network condensation polymers
EP0673253A1 (de) 1992-12-11 1995-09-27 NanoSystems L.L.C. Zusammensetzung gegen übersäuerung und methode zur herstellung
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
JP4126085B2 (ja) 2002-03-15 2008-07-30 富士通株式会社 表示同期方法および表示同期装置
RU2237743C2 (ru) 2002-09-26 2004-10-10 Закрытое акционерное общество "Межотраслевое юридическое агентство "Юрпромконсалтинг" Способ обработки поверхности протяженного изделия, линия и устройство для его осуществления
JP4625724B2 (ja) 2005-06-28 2011-02-02 株式会社ホンダロック 車両盗難防止装置
ES2452025T3 (es) 2005-06-30 2014-03-31 Biocrates Life Sciences Ag Aparato de análisis de un perfil de metabolitos
KR100790837B1 (ko) 2007-04-30 2008-01-03 삼성전자주식회사 휴대용 단말기에서 전류 소모 제어 장치 및 방법
TWI456969B (zh) 2007-08-24 2014-10-11 Htc Corp 可攜式電子裝置
US7965084B2 (en) 2008-04-21 2011-06-21 Formfactor, Inc. Self-monitoring switch
EP2128973B1 (de) 2008-05-27 2011-05-18 ABB Schweiz AG Startvorrichtung für mindestens zwei Synchronmaschinen
US8032846B1 (en) 2010-03-30 2011-10-04 Synopsys, Inc. Efficient provisioning of resources in public infrastructure for electronic design automation (EDA) tasks

Also Published As

Publication number Publication date
CA2158977A1 (en) 1995-11-10
EP1881075B1 (de) 2013-07-24
EP0772689B1 (de) 2007-12-19
DE69535669T2 (de) 2008-12-04
EP0772689A2 (de) 1997-05-14
EP1881075A1 (de) 2008-01-23
WO1995030763A2 (en) 1995-11-16
AU2585395A (en) 1995-11-29
ES2297831T3 (es) 2008-05-01
JP4303315B2 (ja) 2009-07-29
DE69535669D1 (de) 2008-01-31
WO1995030763A3 (en) 1996-04-04
JPH10500287A (ja) 1998-01-13

Similar Documents

Publication Publication Date Title
DE69535669D1 (de) Retrovirale vektoren mit verminderter rekombinationsrate
ATE424463T1 (de) Rekombinationsunfähige retrovirale vektoren
WO1999004026A3 (en) Lentiviral vectors
GB2369121A (en) Producer cell for the production of retroviral vectors
GB2331522A (en) Lentiviral vectors
EG17799A (en) Process for preparing toothpaste compositions
CY1107760T1 (el) Κυτταρα φακοϊικου εγκλεισμου
ITMI931963A1 (it) Procedimento per la preparazione di copolimeri elastomerici dell'etilene e prodotti ottenuti
DE59911900D1 (de) Retrovirale, mit LCMV-Glykoprotein pseudotypisierte Hybrid-Vektoren
FI940867A0 (fi) Ilmentämisrakenteita, jotka sisältävät HIV:iä estäviä antisense- ja muita nukleotidisekvenssejä, retrovirusvektoreita ja näitä sisältäviä yhdistelmäretroviruksia
EP0816487A4 (de) Zelle, die rekombinanten hiv produziert
WO2000040741A3 (en) Lentivirus vector system
DE50113794D1 (de) Verwendung von polysäuren mit enger molmassenverteilung
NO983375D0 (no) Retroviral vektor og anvendelse derav i genterapi
GB1525580A (en) Photocrosslinkable compositions
ATE200912T1 (de) Pseudotypisierte retrovirale vektoren
NO20002013D0 (no) Suspensjonsforpakningscellelinjer for retrovirusvektorer
AR020076A1 (es) LíNEA CELULAR DE EMPAQUETAMIENTO DE RETROVIRUS ANFOTRoPICO, PROCESO PARA SU PRODUCCIoN, Y PROCESO PARA LA PRODUCCIoN DE UN VECTOR RETROVIRAL MEDIANTE LA MISMA.
DE3061271D1 (en) Fluid heat-carrier preparation, and its use
DE69215148D1 (de) Dithiansubstituierte Propenale und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0772689

Country of ref document: EP